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Hemicrania continua (HC) is characterized by a strictly unilateral continuous headache with 
ipsilateral autonomic features and migrainous symptoms that is exquisitely sensitive to 
indomethacin 1.  As more than 30% of patients report side effects with indomethacin there is  
need for an effective, safe alternative.  Although several drugs have been used in open-label 
studies, none offer the same magnitude of response. 
Occipital nerve stimulation (ONS) has been performed in headache conditions such as chronic 
migraine and chronic cluster headache, both conditions with clinical similarities to HC, and 
appears to be a safe, potentially efficacious treatment even in those failing all available medical 
treatments.2  We report the long-term follow-up of a new cohort of 16 HC patients treated with 
ONS. 
PATIENTS AND METHODS 
Sixteen patients with a diagnosis of HC were implanted with bilateral ONS by a single 
specialist team between 2008-2013.  Patients were diagnosed in accordance with the 
International Classification of Headache Disorders criteria 3.  All had unilateral headaches fully 
responsive to an oral or intramuscular Indotest 4 but had suffered intolerable side effects or had 
contraindications to long term use of the drug.  Patients had failed to respond to trials of at least 
five other medications with limited evidence of efficacy in HC: cyclo-oxygenase inhibitors, 
topiramate, verapamil, gabapentin, pregabalin, melatonin and flunarazine. 
Procedures were offered under the supervision of local clinical effectiveness supervisory 
committee and ethical board approval for collection and publication of data obtained.  Surgical 
procedure is described elsewhere5. 
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Data on headache severity, frequency and intensity was collected at baseline and then every 3-
6 months thereafter and was compared using paired t-tests.   
RESULTS 
The group consisted of nine males with a mean age of implant of 50.38 years (36-74) with 
median duration of HC 8.50 years (3-35).  Patients had failed to respond to an average of 8.06 
medications (5-12) and all had dose limiting side effects to indomethacin.  Five patients had 
co-existent headache syndromes and kept separate diaries for these throughout follow-up. 
Follow-up of the cohort was 38.50 months (11-86).  The mean monthly moderate-severe 
headache days fell by 48.9% (p=0.001) (Table 1).  A favorable response, defined as a more 
than 50% reduction in monthly moderate-severe headache days was observed in 50.0% (8/16) 
of patients.   
The 50% response rate in those with multiple phenotypes was 60.0% (3/5) compared to 45.5% 
(5/11) in the HC alone group.  This difference was not statistically significant (p=1.000). 
Adverse event profile was favorable with no infections, lead migrations or electrode erosions 
reported. 
DISCUSSION 
Current literature contains a total of 11 patients with ONS for HC with benefit suggested in at 
least five patients.  However, there is diagnostic uncertainty in some of these patients due to 
lack of documented response to indomethacin.  This new series is, therefore, the first to report 
on prospective ONS outcome data in a cohort of patients all meeting the diagnostic criteria for 
HC.   
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Our open-label prospective series of 16 complex patients, including some with multiple 
phenotypes, adds support to ONS being a potentially efficacious treatment in intractable HC 
when indomethacin is not tolerated.  A total of 50.0% of all patients showed a beneficial 
response with a reduction of 48.9% in monthly moderate-severe headache days.  Daily 
indomethacin usage dropped by 65.1% in those continuing to take it. 
It has been speculated that those with multiple phenotypes show less of a response to ONS than 
those with a single headache type.  However, our data, all be it with small numbers, shows no 
difference between these groups.  Given that ONS is a treatment reported as potentially useful 
for multiple headache conditions, our data suggests that those with multiple phenotypes should 
not be deprived of the treatment just because of concerns of poor outcome.  However, a need 
exists for this to be examined over larger cohorts. 
Improvements were observed in a number of outcome measures including moderate-severe 
headache days, pain intensity and daily headache hours.  Given that there are no guidelines as 
to which measure is most appropriate for HC and that those recommended for chronic migraine 
are based on clinical trial measurements rather than “real-life” patients we feel that further 
work needs to be done to clinically validate outcome measurements in primary headache 
conditions.  At present, the clinical improvements of a patient may not be being adequately 
captured by outcome measures, leading to a discrepancy between what is reported in the 
literature and what is seen in the clinic in ONS patients. 
Occipital nerve stimulation has received major criticism over its adverse event profile.2  
Previous cohorts of ONS in chronic migraine and cluster headache have reported high rates of 
infection, lead migration, erosion of electrodes through the skin and the need for repeated 
surgical interventions.2  However, our cohort shows a favorable adverse event profile even 
after prolonged follow-up.  Only one patient required a surgical intervention (where the system 
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was changed to one suitable for a rechargeable battery) and no infections or lead migrations.  
Our data supports the concept that adverse events can be minimized by ensuring implants are 
carried out by a small number of highly experienced centers. 
There are limitations to this data, including those inherent to any unblended series, but given 
the rarity of HC it is unlikely that an adequately powered, randomized trial with adequate 
placebo will be carried out anytime in the near future.  However, strengths of the series include 
the use of prospective data and a prolonged follow-up period.  The cohort was also based on 
clinical need and as such will be transferable to other patients in similar specialist headache 
centers.  Although a reduction in moderate-severe headache days of 48.9% may not appear 
positive to some, such a response in a highly intractable group of chronic pain patients should, 
instead, be viewed with cautious optimism. 
In conclusion, there is a need for alternatives to indomethacin in HC due to intolerable side 
effects and our series suggests that ONS may provide a useful and safe treatment option even 
after prolonged follow-up.  However, ONS should be reserved for those failing to respond to 
adequate numbers of other medical treatments. 
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